The emerging role of immunotherapy for the treatment of sarcoma. Issue 3 (1st December 2020)

• Record Type: Journal Article
• Authors: Klemen, Nicholas D.; Kelly, Ciara M.; Bartlett, Edmund K.
• Other Names: Brady Mary S. guestEditor.; Sabel Michael S. guestEditor.
• Is Part Of: Journal of surgical oncology. Volume 123:Issue 3(2021)
• Page Start: 730
• Page End: 738
• Publication Date: 2020-12-01
• Subjects: bone sarcoma -- checkpoint inhibition -- immunotherapy -- sarcomas -- soft‐tissue sarcoma; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26306
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Clinicians caring for patients with sarcoma founded the field of cancer immunotherapy. Despite this, contemporary success with immunotherapy for sarcoma has been limited. Here, we review immunotherapy for sarcoma including Coley's toxins, interleukin‐2, adoptive cell transfer, and checkpoint blockade. We detail recent and ongoing efforts to combine checkpoint blockade with other immune modulators, surgery, or radiation. These results, along with ongoing investigations, have identified immunotherapeutic approaches as a promising avenue for progress in advanced sarcomas.